Pharsight

Drugs that contain Tedizolid Phosphate

1. Sivextro patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8420676 CUBIST PHARMS LLC Oxazolidinone derivatives
Feb, 2028

(3 years from now)

US7816379 CUBIST PHARMS LLC Oxazolidinone derivatives
Jun, 2028

(4 years from now)

US10442829 CUBIST PHARMS LLC Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate
Feb, 2030

(5 years from now)

US9624250 CUBIST PHARMS LLC Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate
Feb, 2030

(5 years from now)

US8426389 CUBIST PHARMS LLC Crystalline form of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate
Dec, 2030

(6 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10065947 CUBIST PHARMS LLC Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate
Feb, 2030

(5 years from now)

US9988406 CUBIST PHARMS LLC Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate
Feb, 2030

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 20, 2019
Generating Antibiotic Incentives Now (GAIN) Jun 20, 2024

NCE-1 date: 2023-06-21

Market Authorisation Date: 20 June, 2014

Treatment: Method of treating bacterial infections; Method of treating acute bacterial skin and skin structure infections (absssi) caused by designated susceptible bacteria

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

SIVEXTRO family patents

Family Patents